Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay

Journal of Proteomics

Volumn 74, Issue 10, 2011, Pages 2052-2059

  Cho, Chan Kyung J ^a,b   Drabovich, Andrei P ^b   Batruch, Ihor ^b,c   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biomarker; CEL; CPA1; Down syndrome; DPP4; MMP2; MUC13; Prenatal screening

Indexed keywords

BILE SALT; CARBOXYPEPTIDASE A; DIPEPTIDYL PEPTIDASE IV; GELATINASE A;

AMNION FLUID; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; FETUS DEVELOPMENT; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; SCREENING TEST; SELECTED REACTION MONITORING ASSAY;

AMNIOTIC FLUID; BIOLOGICAL MARKERS; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; PREGNANCY; PRENATAL DIAGNOSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 80052030114     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.05.025     Document Type: Article

References (31)

1. Canfield M.A., Honein M.A., Yuskiv N., Xing J., Mai C.T., Collins J.S., et al. National estimates and race/ethnic-specific variation of selected birth defects in the united states, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006, 76:747-756.
2. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 2004, 5:725-738.
3. Malone F.D., Canick J.A., Ball R.H., Nyberg D.A., Comstock C.H., Bukowski R., et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005, 353:2001-2011.
4. Haddow J.E., Palomaki G.E., Knight G.J., Williams J., Pulkkinen A., Canick J.A., et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992, 327:588-593.
5. Halliday J.L., Watson L.F., Lumley J., Danks D.M., Sheffield L.J. New estimates of down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population. Prenat Diagn 1995, 15:455-465.
6. Cho C.K., Shan S.J., Winsor E.J., Diamandis E.P. Proteomics analysis of human amniotic fluid. Mol Cell Proteomics 2007, 6:1406-1415.
7. Park S.J., Yoon W.G., Song J.S., Jung H.S., Kim C.J., Oh S.Y., et al. Proteome analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proteomics 2006, 6:349-363.
8. Gravett M.G., Novy M.J., Rosenfeld R.G., Reddy A.P., Jacob T., Turner M., et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004, 292:462-469.
9. Cho C.K., Smith C.R., Diamandis E.P. Amniotic fluid proteome analysis from down syndrome pregnancies for biomarker discovery. J Proteome Res 2010, 9:3574-3582.
10. Perluigi M., di Domenico F., Fiorini A., Cocciolo A., Giorgi A., Foppoli C., et al. Oxidative stress occurs early in down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin Appl 2011, 5:167-178.
11. Cheng P.J., Wang T.H., Huang S.Y., Kao C.C., Lu J.H., Hsiao C.H. Differential proteomics analysis of amniotic fluid in pregnancies of increased nuchal translucency with normal karyotype. Prenat Diagn 2011, 31:274-281.
12. Whiteaker J.R., Zhao L., Abbatiello S.E., Burgess M., Kuhn E., Lin C., et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 2011, 10(4). M110.005645 [Electronic publication, 2011 Jan 18].
13. Drabovich A.P., Diamandis E.P. Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. J Proteome Res 2010, 9:1236-1245.
14. Cho C.K., Diamandis E.P. Application of proteomics to prenatal screening and diagnosis for aneuploidies. Clin Chem Lab Med 2011, 49:33-41.
15. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., Pearson T.W. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (siscapa). J Proteome Res 2004, 3:235-244.
16. Soini Y., Satta J., Maatta M., Autio-Harmainen H. Expression of mmp2, mmp9, mt1-mmp, timp1, and timp2 mrna in valvular lesions of the heart. J Pathol 2001, 194:225-231.
17. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kd gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125-2131.
18. Yang Z., Strickland D.K., Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001, 276:8403-8408.
19. Roher A.E., Kasunic T.C., Woods A.S., Cotter R.J., Ball M.J., Fridman R. Proteolysis of a beta peptide from Alzheimer disease brain by gelatinase a. Biochem Biophys Res Commun 1994, 205:1755-1761.
20. Yankner B.A., Lu T. Amyloid beta-protein toxicity and the pathogenesis of alzheimer disease. J Biol Chem 2009, 284:4755-4759.
21. Horstmann S., Budig L., Gardner H., Koziol J., Deuschle M., Schilling C., Wagner S. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr 2010, 22:966-972.
22. Bellini C., Rutigliani M., Boccardo F.M., Bonioli E., Campisi C., Grillo F., et al. Nuchal translucency and lymphatic system maldevelopment. J Perinat Med 2009, 37:673-676.
23. Shin J.W., Jurisic G., Detmar M. Lymphatic-specific expression of dipeptidyl peptidase iv and its dual role in lymphatic endothelial function. Exp Cell Res 2008, 314:3048-3056.
24. Ikushima H., Munakata Y., Ishii T., Iwata S., Terashima M., Tanaka H., et al. Internalization of cd26 by mannose 6-phosphate/insulin-like growth factor ii receptor contributes to T cell activation. Proc Natl Acad Sci U S A 2000, 97:8439-8444.
25. Kodvawala A., Ghering A.B., Davidson W.S., Hui D.Y. Carboxyl ester lipase expression in macrophages increases cholesteryl ester accumulation and promotes atherosclerosis. J Biol Chem 2005, 280:38592-38598.
26. Bocconi L., Nava S., Fogliani R., Nicolini U. Trisomy 21 is associated with hypercholesterolemia during intrauterine life. Am J Obstet Gynecol 1997, 176:540-543.
27. Prasher V.P., Airuehia E., Patel A., Haque M.S. Total serum cholesterol levels and Alzheimer's dementia in patients with down syndrome. Int J Geriatr Psychiatry 2008, 23:937-942.
28. Williams S.J., Wreschner D.H., Tran M., Eyre H.J., Sutherland G.R., McGuckin M.A. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem 2001, 276:18327-18336.
29. Chauhan S.C., Vannatta K., Ebeling M.C., Vinayek N., Watanabe A., Pandey K.K., et al. Expression and functions of transmembrane mucin muc13 in ovarian cancer. Cancer Res 2009, 69:765-774.
30. Walsh M.D., Young J.P., Leggett B.A., Williams S.H., Jass J.R., McGuckin M.A. The muc13 cell surface mucin is highly expressed by human colorectal carcinomas. Hum Pathol 2007, 38:883-892.
31. Moehle C., Ackermann N., Langmann T., Aslanidis C., Kel A., Kel-Margoulis O., et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med 2006, 84:1055-1066.